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Abstract
Background: Dexketoprofen, an NSAID used in the management of acute and chronic pains, is
licensed in several countries but has not previously been the subjected of a systematic review. We
used published and unpublished information from randomised clinical trials (RCTs) of
dexketoprofen in painful conditions to assess evidence on efficacy and harm.
Methods: PubMed and Cochrane Central were searched for RCTs of dexketoprofen for pain of
any aetiology. Reference lists of retrieved articles and reviews were also searched. Menarini Group
produced copies of published and unpublished studies (clinical trial reports). Data were abstracted
into a standard form. For studies reporting results of single dose administration, the number of
patients with at least 50% pain relief was derived and used to calculate the relative benefit (RB) and
number-needed-to-treat (NNT) for one patient to achieve at least 50% pain relief compared with
placebo.
Results: Thirty-five trials were found in acute pain and chronic pain; 6,380 patients were included,
3,381 receiving dexketoprofen. Information from 16 trials (almost half the total patients) was
obtained from clinical trial reports from previously unpublished trials or abstracts. Almost all of the
trials were of short duration in acute conditions or recent onset pain.
All 12 randomised trials that compared dexketoprofen (any dose) with placebo found
dexketoprofen to be statistically superior. Five trials in postoperative pain yielded NNTs for 12.5
mg dexketoprofen of 3.5 (2.7 to 4.9), 25 mg dexketoprofen of 3.0 (2.4 to 3.9), and 50 mg
dexketoprofen of 2.1 (1.5 to 3.5). In 29/30 active comparator trials, dexketoprofen at the dose used
was at least equivalent in efficacy to comparator drugs. Adverse event withdrawal rates were low
in postoperative pain and somewhat higher in trials of longer duration; no serious adverse events
were reported.
Conclusion: Dexketoprofen was at least as effective as other NSAIDs and paracetamol/opioid
combinations. While adverse event withdrawal was not different between dexketoprofen and
comparator analgesics, the different conditions and comparators studies precluded any formal
analysis. Exposure was limited, and no conclusions could be drawn about safety in terms of serious
adverse events like gastrointestinal bleeding or cardiovascular events.
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Introduction
Racemic ketoprofen is used as an analgesic and an anti-
inflammatory agent, and is one of the most potent in vitro
inhibitors of prostaglandin synthesis, but is also impli-
cated as having an association with higher risk of serious
gastrointestinal bleeding events than other NSAIDs [1,2].
The analgesic effect is due to the S(+)-enantiomer (dexke-
toprofen), while the R(-)-enantiomer is devoid of analge-
sic activity [3]. Because the R(-)-enantiomer does appear
to have ulcerogeneic activity, at least in the rat [3,4], the
implication is that use of dexketoprofen alone should
produce equivalent analgesia to double-dose ketoprofen,
but at lower risk of harm. At least one case-control study
in Spain appears to confirm a lower rate of serious gas-
trointestinal harm with dexketoprofen than ketoprofen,
but with overlapping confidence intervals and small num-
bers of events [2]. Other authorities regard the approach
of using an active enantiomer as a tromethamine salt as
attractive on theoretical grounds [4].
Formulation is important, especially the use of the
trometamol salt for rapid absorption [3]. In healthy vol-
unteers absorption of dexketoprofen from dexketoprofen
trometamol capsules was similar to ketoprofen, while the
extent of absorption of dexketoprofen free acid was signif-
icantly lower than that for ketoprofen [5]. Dexketoprofen
trometamol showed the most rapid absorption rate, with
highest maximum plasma concentration and shortest
time to maximum values, while ketoprofen had an inter-
mediate absorption rate, and dexketoprofen free acid the
slowest absorption rate. After repeated-dose administra-
tion of dexketoprofen trometamol, the pharmacokinetic
parameters were similar to those obtained after single
doses, indicating that no drug accumulation occurred [5].
Food slowed absorption of dexketoprofen, even from the
trometamol salt [6].
Dexketoprofen is licensed in a number of countries
around the world. Oral dexketoprofen was approved in
the European Countries through a Mutual Recognition
Procedure on 13th February 1998 and the injectable for-
mulation on 25th October 2002. Dexketoprofen has not
been subjected to the scrutiny of a systematic review, and
not reviewed at all since preclinical and clinical develop-
ment studies were reviewed over a decade ago [7]. We
sought to obtain published and unpublished information
from randomised clinical trials of dexketoprofen to assess
the available evidence on efficacy and harm.
Systematic reviews are useful for pulling together all the
studies on a topic – here randomised, double blind com-
parative trials of dexketoprofen in painful conditions. By
assessing trial quality and validity [8,9] it is possible to
eliminate trials likely to be biased, and biased trials are
much more likely to over-estimate treatment effects. Accu-
mulating many similar trials together reduces the possibil-
ity of variation in efficacy estimates because of the
random play of chance, and should improve assessment
of harm.
Methods
We searched PubMed, and Cochrane Central up to Octo-
ber 2008 for randomised controlled trials using dexketo-
profen to treat pain of any aetiology. The detailed search
strategy included use of the drug name dexketoprofen
anywhere in an article, together with the publication
descriptor of randomised trial; this was modified for the
different databases. Reference lists of retrieved articles and
reviews were also searched for relevant trials. In addition,
Menarini Group also produced copies of published and
unpublished studies, the latter in the form of clinical trial
reports.
For inclusion, trials had to be at least randomised, and use
dexketoprofen to treat adult patients with pain of any ori-
gin. Trials had to have a minimum of 10 patients per treat-
ment arm, and at least one dose of dexketoprofen given by
any route of administration, at any dose, and with any
comparator.
The abstracts were read, and potentially useful reports
retrieved in full paper copy. No information was taken
from posters or abstracts unless supplemented by details
from a clinical trial report. Decisions on inclusion or
exclusion of trials, assessment of trial quality and validity
and all data extraction were made independently by both
reviewers, with discrepancies resolved by consensus.
Methodological quality of included studies was assessed
using the validated 5-point Oxford quality scale [8] utilis-
ing reporting of randomisation, blinding and withdraw-
als. The maximum score possible was 5 points, and no
study could be included with fewer than 2 points (one for
randomisation and one for blinding). Study validity was
assessed using the validated Oxford Pain Validity Scale
(OPVS) 16-point scale [9]. Only trials that were both ran-
domised and double blind were used for calculation of
numbers needed to treat.
Data were abstracted into a standard form. Information
was extracted from the trials according to painful condi-
tion, with details of drugs, dose, route of administration,
patient numbers, treatment and observation schedule,
outcomes measured, and main efficacy and safety results.
For studies reporting results of single dose administration
we sought to the outcome of at least 50% pain relief. For
each report, mean TOTPAR (total pain relief) or SPID
(summed pain intensity difference) for active and placebo
groups were converted to %maxTOTPAR or %maxSPIDBMC Clinical Pharmacology 2008, 8:11 http://www.biomedcentral.com/1472-6904/8/11
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by division into the calculated maximum value [10]. The
proportion of patients in each treatment group who
achieved at least 50%maxTOTPAR was calculated using
verified equations [11-13]. These proportions were then
converted into the number of patients achieving at least
50%maxTOTPAR by multiplying by the total number of
patients in the treatment group. Information on the
number of patients with at least 50%maxTOTPAR for
active treatment and placebo was then used to calculate
relative benefit (RB) and number needed-to-treat (NNT).
Pain measures accepted for the calculation of TOTPAR or
SPID were:
￿ 5-point categorical pain relief (PR) scales with compara-
ble wording to "none, slight, moderate, good or com-
plete"
￿ 4-point categorical pain intensity (PI) scales with com-
parable wording to "none, mild, moderate, severe"
￿ Visual analogue scales (VAS) for pain relief
￿ VAS for pain intensity
￿ 5-point categorical global scale with the wording "poor,
fair, good, very good, excellent" [14]
Other measures of pain relief were abstracted where
reported and appropriate. Secondary outcomes were with-
drawals (all cause, lack of efficacy and adverse events) and
adverse events (patients with at least one adverse event,
serious adverse events, and specific adverse events). We
anticipated that reporting of adverse events would vary
between trials with regard to the terminology used,
method of ascertainment, and categories reported (e.g.
occurring in ≥ 5% of patients or where there was a statisti-
cally significant difference between treatment groups).
Guidelines for quality of reporting of meta-analyses were
followed where appropriate [15]. The prior intention was
to pool data where there was clinical and methodological
homogeneity, with similar patients, dose, duration, out-
comes, and comparators, but not where numbers of
events were small, and random chance could dominate
effects of treatment [16]. Homogeneity tests and funnel
plots, though commonly used in meta-analysis, were not
used here because they have been found to be unreliable
[17,18]. Instead clinical homogeneity was examined
graphically [19]. Relative benefit (or risk) and number-
needed-to-treat or harm (NNT or NNH) were calculated
with 95% confidence intervals. Relative benefit or risk was
calculated using a fixed effects model [20], with no statis-
tically significant difference between treatments assumed
when the 95% confidence intervals included unity. We
added 0.5 to treatment and comparator arms of trials in
which at least one arm had no events. Number-needed-to-
treat (or harm) was calculated by the method of Cook and
Sackett [21] using the pooled number of observations
only when there was a statistically significant difference of
relative benefit or risk (where the confidence interval did
not include 1). There was a prior intention to carry out
sensitivity analyses for high versus low trial quality (< 3 vs
≥ 3), dose, and condition. Information would be reported
with any number of patients, but not regarded unless
there was a minimum of two trials or 250 patients [16].
Results
Thirty-five trials were found in acute and chronic pain, 32
of which had reporting quality of 3/5 or better and 30 of
which had OPVS score of at least 9/16 (Table 1). Ten trials
had individual group sizes of 100 patients or more. The
total number of patients was 6,380, of whom 3381
received dexketoprofen (Table 1). More patients were in
trials of oral therapies (4,249 total, 2,270 on dexketopro-
fen) than trials of intramuscular or intravenous therapies
(2,131 total, 1,111 on dexketoprofen). Information from
16 trials (46%) with 3,253 patients (51%) was obtained
from clinical trial reports from previously unpublished tri-
als, or trials published only as abstracts. All 16 clinical trial
reports had a quality score of at least 3/5 and an OPVS
score of at least 9/16. Almost all of the trials were of short
duration in acute conditions, or for recent onset pain.
Only two, in osteoarthritis, investigated efficacy in
chronic painful conditions.
All 12 randomised trials that compared dexketoprofen, at
any dose, with placebo found dexketoprofen to be statis-
tically superior (Table 1). More common was a compari-
son of dexketoprofen with an active comparator, which
happened in 30 trials. In 29 of these 30 trials, dexketopro-
fen at the dose used was at least equivalent in efficacy to
the comparator drugs with known analgesic efficacy.
Single and multiple dose trials in dental pain
Seven randomised trials [22-29] examined the analgesic
efficacy of oral dexketoprofen in 994 patients studied in
the third molar extraction pain model, 618 of whom
received dexketoprofen (Additional file 1). One trial was
published as an abstract [29], with data taken from a clin-
ical trial report [23]. Six of the seven trials were both ran-
domised and double blind, and had quality scores of 4 or
5 of the maximum 5 points and had OPVS scores of at
least 9/16. One open trial [27] scored only 1 out of 5.
Three good quality trials were standard pain models
reporting pain intensity or pain relief for four to six hours
after the initial dose, had patients with moderate or severe
pain at entry, and measured pain intensity and pain relief
over six hours [24,25,28]. In these three trials dexketopro-
fen at doses of 10 or 12.5 mg (Figure 1), 20 or 25 mg (Fig-BMC Clinical Pharmacology 2008, 8:11 http://www.biomedcentral.com/1472-6904/8/11
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ure 2), and 50 mg were all significantly superior to
placebo, with NNTs for at least 50% pain relief over six
hours compared with placebo of 3.0 (2.3 to 4.4), 2.6 (2.0
to 3.5), and 2.1 (1.5 to 3.5) respectively (Table 2). One
trial [28] used ketoprofen 50 mg, and that was also signif-
icantly better than placebo. The one other trial that used
placebo [26] reported data at eight hours, and appeared to
measure pain scores after use of remedication. Despite
that, dexketoprofen 25 mg was significantly better than
placebo.
Dexketoprofen 12.5 mg and 25 mg were both superior to
dipyrone 575 mg in the single dose phase of a multiple
dose trial [22]. There was no difference between use of pre
and postsurgical dexketoprofen in another trial [23,29].
The final trial [27] compared dexketoprofen 25 mg with
ibuprofen 600 mg, but no interpretation could be made in
this case because it included patients with mild pain
which is known to desensitise pain trials.
Single and multiple dose trials in postsurgical pain
Thirteen randomised trials [30-43] examined the analge-
sic efficacy of dexketoprofen in 2135 patients studied in
postsurgical pain, 997 of whom received dexketoprofen
(Additional file 2). One trial was published as an abstract
[31] with data taken from a clinical trial report [42].
Twelve of the 13 trials were both randomised and double
blind, and 11 had quality scores of three or more of the
maximum 5 points and at least 9 on an OPVS (Table 1).
Eight trials (1212 patients) used oral dexketoprofen and
four (923 patients) intramuscular or intravenous dexketo-
profen. Eight of the 13 trials were in major orthopaedic
surgery (mainly knee and hip surgery), the others involv-
ing arthroscopy, bunionectomy, hernias, abdominal hys-
terectomy, and abdominal surgery.
Two good quality trials were standard pain models report-
ing pain intensity or pain relief for four to six hours after
the initial dose, had patients with moderate or severe pain
at entry, and measured pain intensity and pain relief over
six hours [32,34]. In these trials oral dexketoprofen at
doses of 10 or 12.5 mg (Figure 1) and 20 or 25 mg (Figure
2) were significantly superior to placebo, with NNTs for at
least 50% pain relief over six hours compared with pla-
cebo of 4.4 (2.8 to 9.7) and 3.7 (2.5 to 7.0) respectively
(Table 2). Four of the nine oral trials used placebo, and in
these dexketoprofen was significantly better than placebo
on at least one measure in three trials [34,39,43], but not
in the fourth [32]. Ketoprofen 50 mg was not significantly
better than placebo in the two trials that used it [32,34].
Where there was an active comparator, dexketoprofen 25
mg appeared to be equivalent to tramadol 50 mg [42,33],
diclofenac 50 mg [36], and paracetamol 500 mg plus
codeine 22.5 mg [38]. Three trials compared dexketopro-
fen 25 mg with ketoprofen 50 mg; while there was no dif-
ference in one small trial [41], ketoprofen appeared to be
less effective in two others [32,34].
Two trials [35,40] used intramuscular administration of
dexketoprofen at doses of 25 mg or 50 mg twice a day, and
two [30,37] intravenous administration of 50 mg three
Table 1: Summary table of randomised trials included in the review
Number of: Number of patients
Pain 
condition
Studies Studies 
with QS 
≥ 3/5
Studies with 
OPVS ≥ 9/16
Trials of 
group size ≥ 
100
In total Given 
dexketoprofen
Better than 
placebo/total 
comparisons
At least equivalent 
to effective 
analgesic/total 
comparisons
Dental pain 7 6 6 0 994 618 4/4 3/4
Postsurgical 13 11 11 2 2185 1022 7/7 11/11
Renal colic 3 3 3 3 838 526 3/3
Gynaecologic 
pain
2 2 1 1 350 200 1/1 2/2
Lower limb 
injury
11 1 0 1 2 2 6 5 1 / 1
Ankle sprain 1 1 1 1 209 106 1/1
Acute bone 
pain in cancer
11 1 0 1 1 5 5 7 1 / 1
Acute low 
back pain
55 5 31 2 6 7 6 3 5 5 / 5
OA/RA 2 2 2 0 300 152 2/2
Total 35 32 31 10 6380 3381 12/12 29/30
QS = quality score; OPVS = Oxford Pain Validity Score; OA = osteoarthritis; RA = rheumatoid arthritisBMC Clinical Pharmacology 2008, 8:11 http://www.biomedcentral.com/1472-6904/8/11
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times a day, or 50 mg twice a day. Time intervals between
doses were 6–8 h and 12 hours in the different studies.
Three [35,37,40] made a comparison with placebo, and in
all three doses of dexketoprofen were significantly better
than placebo on at least one measure of efficacy. All four
trials had an active comparator, and dexketoprofen at the
dose studied was at least as effective as ketoprofen 100 mg
[30,40], tramadol 100 mg [37], and diclofenac 75 mg
twice a day [35]. There was a suggestion of somewhat bet-
ter efficacy between three and eight hours, and lower mor-
phine requirements, than diclofenac 75 mg twice a day
[35].
Overall results of single dose dexketoprofen in acute pain, 
and comparison with ketoprofen
Combining three third molar extraction and two postsur-
gical trials (Table 2) gave NNTs for at least 50% pain relief
for 12.5 mg dexketoprofen of 3.5 (2.7 to 4.9), 25 mg
dexketoprofen of 3.0 (2.4 to 3.9), and 50 mg dexketopro-
fen of 2.1 (1.5 to 3.5). The overlapping confidence inter-
vals and formal testing [44] for difference between NNTs
showed no statistical difference between 12.5 mg and 25
mg doses.
Several trials used both dexketoprofen and ketoprofen.
Table 2 also shows the comparisons between 12.5 mg and
25 mg dexketoprofen and 50 mg ketoprofen, and 50 mg
dexketoprofen and 100 mg ketoprofen. While the propor-
tion of patients achieving at least 50% pain relief was con-
sistently higher with dexketoprofen, this did not reach
statistical significance with any comparison. However,
when 25 mg or 50 mg dexketoprofen were compared with
50 mg or 100 mg ketoprofen (that is, double the dose, Fig-
ure 3), statistical significance was achieved, with a number
needed to treat of 8.8 (5.1 to 33). That means that for
every nine persons treated with 25 mg or 50 mg dexketo-
Table 2: Results of single dose trials in dental and postsurgical pain for comparison of dexketoprofen with placebo, and dexketoprofen 
with ketoprofen
Dexketoprofen versus placebo
Number of Percent of patients with at least 50% pain 
relief
Dexketoprofen dose 
(mg)
Trials Patients Dexketoprofen Placebo Relative benefit 
(95% CI)
NNT (95% CI)
All trials
10/12.5 mg 5 462 45 17 3.4 (2.2 to 5.6) 3.5 (2.7 to 4.9)
20/25 mg 5 455 50 17 3.9 (2.4 to 6.3) 3.0 (2.4 to 3.9)
50 mg 1 67 56 8 6.7 (1.7 to 26) 2.1 (1.5 to 3.5)
Dental
10/12.5 mg 3 261 47 13 3.5 (2.2 to 5.6) 3.0 (2.3 to 4.4)
20/25 mg 3 254 52 13 3.9 (2.4 to 6.3) 2.6 (2.0 to 3.5)
50 mg 1 67 56 8 6.7 (1.7 to 26) 2.1 (1.5 to 3.5)
Postsurgical
10/12.5 mg 2 201 43 21 2.1 (1.4 to 3.3) 4.4 (2.8 to 9.7)
20/25 mg 2 201 47 21 2.3 (1.5 to 3.6) 3.7 (2.5 to 7.0)
Dexketoprofen versus ketoprofen
Number of Percent of patients with at least 50% pain 
relief
Dexketoprofen/
ketoprofen dose (mg)
Trials Patients Dexketoprofen Ketoprofen Relative benefit 
(95% CI)
NNT (95% CI)
All trials
12.5 vs 50 3 287 44 35 0.8 (0.5 to 1.2) not calculated
25 vs 50 3 284 51 35 1.1 (0.7 to 1.5) not calculated
50 vs 100 1 247 82 77 1.1 (0.9 to 1.2) not calculated
25/50 vs 50/100 4 531 65 54 1.2 (1.1 to 1.4) 8.8 (5.1 to 33)BMC Clinical Pharmacology 2008, 8:11 http://www.biomedcentral.com/1472-6904/8/11
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profen, one more would have at least 50% pain relief than
if the same nine patients were treated with ketoprofen 50
mg or 100 mg.
Single dose trials in pain of renal colic
Three randomised trials [45-47] examined the analgesic
efficacy of dexketoprofen 25 mg and 50 mg intramuscu-
larly, and 25 mg and 50 mg intravenously, in 838 patients
studied in pain of renal colic, 526 of whom received
dexketoprofen (Additional file 3). All of the trials were
both randomised and double blind, all had quality scores
of three or more of the maximum 5 points and at least 9
points on an OPVS. One trial [45] used intramuscular
dexketoprofen and two [46,47] intravenous dexketopro-
fen.
None of the trials had a placebo control, and all examined
efficacy over six hours after a single dose n pain of moder-
ate or severe intensity. Intramuscular dexketoprofen 25
mg and 50 mg were indistinguishable from intramuscular
dipyrone 2000 mg [45]. Intravenous dexketoprofen 25
mg or 50 mg were indistinguishable from intravenous
dipyrone 2000 mg or more [46], and intravenous dexke-
toprofen 50 mg was indistinguishable from intravenous
ketoprofen 100 mg [47].
L'Abbé plot of individual trials of dexketoprofen 10/12.5 mg  compared with placebo in dental and postsurgical pain Figure 1
L'Abbé plot of individual trials of dexketoprofen 10/
12.5 mg compared with placebo in dental and post-
surgical pain. Inset scale shows size of trial. Light symbols = 
dental trials, dark symbols = postsurgical trials.
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At least 50% pain relief with placebo
0
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L'Abbé plot of individual trials of dexketoprofen 20/25 mg  compared with placebo in dental and postsurgical pain Figure 2
L'Abbé plot of individual trials of dexketoprofen 20/
25 mg compared with placebo in dental and postsur-
gical pain. Inset scale shows size of trial. Light symbols = 
dental trials, dark symbols = postsurgical trials.
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L'Abbé plot of individual trials of dexketoprofen compared  with double dose of ketoprofen in dental and postsurgical  pain Figure 3
L'Abbé plot of individual trials of dexketoprofen 
compared with double dose of ketoprofen in dental 
and postsurgical pain. Inset scale shows size of trial. Light 
symbols = 25 mg vs 50 mg, dark symbols = 50 mg vs 100 mg.
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Multiple dose trials in acute low back pain
Five trials [48-53] examined short-term use of dexketo-
profen in acute low back pain, generally over about a week
(Additional file 4); one was published in German [50],
but data were taken from a clinical trial report [49]. All of
the trials were both randomised and double blind, all had
quality scores of three or more of the maximum 5 points
and at least 9 points on an OPVS. One shorter trial com-
pared 50 mg twice-daily intramuscular dexketoprofen
with 75 mg diclofenac in almost 400 patients [48]. Four
oral comparisons of dexketoprofen 25 mg three times
daily over 4–7 days in patients with pain of acute onset
back pain of at least moderate severity showed similar effi-
cacy to diclofenac 150 mg daily [51], tramadol 150 mg
daily [49,52], and paracetamol 800 mg plus dextropro-
poxyphene 60 mg daily [53].
Single and multiple dose trials in other acute painful 
conditions
Five randomised trials [54-58] have examined the analge-
sic efficacy in other acute painful conditions in 796
patients, 428 of whom received oral dexketoprofen,
mainly at 25 mg (Additional file 5). All of the trials were
both randomised and double blind, all had quality scores
of three or more of the maximum 5 points and at least 9
points on an OPVS. Only one trial [54] was placebo con-
trolled, and looked at efficacy of 12.5 mg and 25 mg of
dexketoprofen in comparison with 50 mg ketoprofen in
52 women with dysmenorrhoea; all three active treat-
ments were superior to placebo, but not different one
from another.
Dexketoprofen 25 mg orally was found to be superior to
injections of mepivacaine into the uterine cervix in pro-
ducing significantly lower pain scores over 30–120 min-
utes after hysteroscopy [55] as well as being better than 50
mg diclofenac for lower limb injury between 15 and 60
minutes [56]. Over four days there was no difference
between three times daily ketoprofen 25 mg or paraceta-
mol 500 mg plus codeine 60 mg in the treatment of ankle
sprains [57]. In patients with cancer who developed bone
cancer pain of at least moderate intensity, and who had
not previously been treated with a continuous regimen of
opioids or NSAIDs in the previous 15 days, there was no
difference between 25 mg dexketoprofen and 10 mg
ketorolac over seven days [58].
Multiple dose trials in arthritis
Two trials tested dexketoprofen 25 mg three times a day
against ketoprofen 150 mg daily and diclofenac 150 mg
daily in patients with established arthritis [59,60](Addi-
tional file 6). Both trials were randomised and double
blind, all had quality scores of three or more of the maxi-
mum 5 points and at least 9 points on an OPVS. The trials
had a flare design in which patients discontinued previous
treatment. Over two or three weeks of treatment there
were no differences between dexketoprofen and
diclofenac at these doses [60], though dexketoprofen 75
mg daily was superior to ketoprofen 150 mg daily [59].
Overall comparison between dexketoprofen and 
ketoprofen
The main comparisons between dexketoprofen and keto-
profen occurred within the dental trials and those in post-
surgical pain. There were three other comparisons. One
comparison of intravenous administration in renal colic
showed no difference between dexketoprofen 50 mg and
ketoprofen 100 mg [47]. Of the two oral comparisons
there was no difference between dexketoprofen 12.5 mg
or 25 mg and ketoprofen 50 mg [54], while the one com-
parison between 25 mg dexketoprofen with 50 mg keto-
profen in arthritis showed better results for dexketoprofen
[59].
Adverse events
Additional files 1, 2, 3, 4, 5, 6 records adverse events
reported in the trials, in terms of the numbers of patients
reporting at least one adverse event, all cause withdrawals,
and withdrawal due to an adverse event. Adverse event
reporting was generally poor. Because trials varied from
single dose to three weeks duration, with different routes
of administration, drug doses, comparators, and condi-
tion, sensible analysis of adverse events were not possible.
Because adverse event withdrawal is a significant event,
and attempt was made to examine adverse event with-
drawal rates in trials where at least two doses of drug were
given. Because the rate of adverse event withdrawals is
likely to be a function of the number of doses given, these
were split by relatively shorted duration studies predomi-
nantly less than two days (dental and postsurgical pain)
and relatively longer studies predominantly more two
days or longer (acute painful conditions, back pain, and
arthritis) (Table 3).
The choice of two doses was simply because withdrawal is
not really an option after a single dose and is unlikely to
be recorded in the same was as in multiple dose studies.
In both comparisons dexketoprofen (all doses) provided
the about half the total number of patients (Table 3).
Adverse event withdrawal rates were low, at about 2% or
below in dental and postsurgical pain, and somewhat
higher in trials of longer duration. The adverse event with-
drawal rate for dexketoprofen was not out of line with
other drugs, though limited numbers prevented any firm
conclusions, and statistical tests were not deemed sensi-
ble.
No serious adverse events, like gastrointestinal bleeding,
myocardial infarction, or death, were reported in any trial.BMC Clinical Pharmacology 2008, 8:11 http://www.biomedcentral.com/1472-6904/8/11
Page 8 of 11
(page number not for citation purposes)
Discussion
This review found reports of 34 randomised trials of
dexketoprofen, predominantly of sufficiently high report-
ing quality to avoid bias [9,61]. To be comprehensive any
randomised trial was included, but only higher quality tri-
als (randomised, double blind) were used to calculate
NNTs. Almost half the trials and just over half the patients
(51%) were in trials that had not previously been pub-
lished in full, and so this review doubles the amount of
information previously available on dexketoprofen. Sig-
nificant numbers of otherwise unpublished pain trials
have been found before in systematic reviews [62,63].
Nearly all trials appeared to be valid as judged by quality
scores and OPVS scores. The two arthritis trials, at three
weeks, were considerably shorter than the current norm in
arthritis trials, which now is 6–12 weeks. The trials tended
to be relatively small, with an average of 190 patients split
between several treatment groups, and while they were
sufficient to yield statistical results regarding the direction
of any effect, they were not individually large enough to
comment sensibly on its magnitude [16]. While 10 trials
had group sizes of at least 100 patients, these were spread
throughout the different conditions studied (Table 1).
The small size and generally short duration of the trials
limits transfer of knowledge to clinical practice. The trials
tell us about whether dexketoprofen is an analgesic. They
do not tell us how best to use it in any particular painful
condition.
Meta-analysis of all trials was not possible because of the
differences between them in terms of painful condition
being treated, dose and route of administration of dexke-
toprofen, duration of therapy, and outcomes reported.
Vote counting only was possible, and this showed that all
12 trials with a placebo comparison showed dexketopro-
fen to be better than placebo, and that 29/30 trials
showed dexketoprofen to be at least equivalent to an
active comparator of known analgesic efficacy (Table 1).
The one area where meta-analysis was possible was that of
single dose oral administration in dental and postsurgical
pain (Table 2). Based on limited data there appeared to be
a dose-response, with better (lower) NNTs with higher
doses of dexketoprofen. The best general comparison with
other analgesics probably comes from the dental pain
model, because these trials are consistently conducted in
very similar patients, using similar methods and out-
comes, and tried and tested methods [64,65]. The NNT for
dexketoprofen compared with placebo for at least 50%
pain relief over 4–6 hours was 2.6, comparable to ibupro-
fen 200–600 mg (NNTs 2.2–2.8) and diclofenac 50 mg
(NNT 2.1), and better than paracetamol 1000 mg (NNT
3.7) [64]. Limited numbers of patients for some of these
drugs and doses make it invidious to push these compar-
isons too far, but at least it can be said that oral dexketo-
profen 25 mg is an effective analgesic according to present
standards. As yet we do not have sufficient or consistent
information across systematic reviews of single dose anal-
gesics to make comparisons of duration of analgesia
(median time to remedication, or percentage of patients
remedicating in a fixed time, for instance), though this
would be useful additional information [66].
There available evidence is that analgesia with dexketo-
profen is equivalent to analgesia obtained with double the
dose of ketoprofen. In single doses in acute pain, there is
a hint even of superior analgesia than double dose keto-
profen (Figure 3, Table 2), and there is at least equivalence
in three other trials.
Again, the varied nature of the studies precluded any for-
mal meta-analysis of adverse events. What could be done
was a descriptive analysis of adverse event withdrawals in
trials with at least two doses of dexketoprofen. The split by
relatively short term studies in dental and postsurgical
pain, and somewhat longer studies in acute pain, back
pain, and arthritis (Table 3) appeared to make sense, as
withdrawal rates tended to be somewhat higher in the
longer duration studies. Dexketoprofen adverse event
withdrawals were not higher than other effective analge-
sics, based on the limited data available.
Table 3: Adverse event withdrawal rates in trials where at least two doses of drug were given
Dental and postsurgical pain Other acute, back pain, arthritis
Drug Number of patients Adverse event withdrawal (%) Number of patients Adverse event withdrawal (%)
Placebo 236 2.5 no data
Dexketoprofen 652 1.8 844 3.2
Ketoprofen 301 1.3 152 7.9
Diclofenac 80 0.0 272 3.7
Tramadol 72 1.4 247 9.7
Paracetamol + opioid 100 0.0 167 1.2BMC Clinical Pharmacology 2008, 8:11 http://www.biomedcentral.com/1472-6904/8/11
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No conclusions could be drawn about serious adverse
events like serious gastrointestinal bleeding, cardiovascu-
lar events, or mortality. Gastrointestinal bleeding and car-
diovascular events tend to occur at a rate of about 1% a
year in randomised trials in arthritis [67]. Trials of dexke-
toprofen lasted only three weeks with arthritis, and barely
a week with most trials. In that circumstance, the rate of a
serious adverse event would be expected in about 1 in
5,000 patients (1 in 100 multiplied by 50), and only
3,200 patients were in trials other than dental or postsur-
gical pain. Additionally, a number of those trials were in
patients substantially younger than those in arthritis tri-
als, with substantially lower baseline risk, decreasing the
potential risk even lower than 1 in 5,000. The absence of
serious events should not, therefore, be taken as an
absence of risk, because the quantity, type and duration of
studies precludes any such conclusion.
Conclusion
This review doubles the amount of information available
concerning analgesic efficacy of dexketoprofen. That effi-
cacy was apparent in single dose in dental and postsurgi-
cal pain, where NNTs for at least 50% pain relief over 4–6
hours compared with placebo were similar to other effec-
tive analgesics. In vote-counting, dexketoprofen was at
least as effective as other analgesics in 29/30 trials. While
adverse event withdrawal was not different between
dexketoprofen and comparator analgesics, the different
conditions and comparators studies precluded any formal
analysis. The amount of exposure was limited, and no
conclusions could be drawn about safety in terms of seri-
ous adverse events like gastrointestinal bleeding or cardi-
ovascular events.
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